<DOC>
	<DOCNO>NCT02279719</DOCNO>
	<brief_summary>This open label , three-arm , phase 1 dose escalation study phase 2 study BBI608 combination sorafenib , BBI503 combination sorafenib . The study population adult patient advance hepatocellular carcinoma receive systemic chemotherapy .</brief_summary>
	<brief_title>A Study BBI608 Combination With Sorafenib , BBI503 Combination With Sorafenib Adult Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description>This open label , three-arm , phase 1 dose escalation study phase 2 study BBI608 combination sorafenib , BBI503 combination sorafenib . The study population adult patient advance hepatocellular carcinoma ( HCC ) receive systemic chemotherapy . The phase 1 portion involve dose-escalation BBI608 administer combination fix start dose sorafenib ( Arm 1 ) , dose escalation BBI503 administer combination fix start dose sorafenib ( Arm 2 ) . The fixed start dose-level sorafenib arm 400 mg twice daily ( 800 mg total daily dose ) . Eligible patient randomize either Arm 1 Arm 2 . The phase 2 portion open-label , 3-arm , randomized trial patient advance HCC receive prior systemic treatment . Patients randomize receive either , Arm 1 : sorafenib administer combination BBI608 ( RP2D determine BBI608 plus sorafenib phase 1 portion ) ; Arm 2 : sorafenib combination BBI503 ( RP2D determine BBI503 plus sorafenib phase 1 portion ) , Arm 3 : sorafenib alone start dose 400 mg twice daily . The start dose sorafenib study arm .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Inclusion Criteria 1 . Signed write informed consent must obtain document accord International Conference Harmonisation ( ICH ) local regulatory requirement 2 . Histologically cytologically confirm hepatocellular carcinoma metastatic , unresectable , recurrent . 1 . Patients must candidate curative resection 2 . Patients recurrent disease one prior resection may eligible , provide candidate curative resection . 3 . Patients recurrent hepatocellular carcinoma follow hepatic transplantation exclude unless follow criterion meet : i. Transplantation perform least 6 month prior relapse HCC . ii . Patients stable immune suppressive therapy clinical evidence rejection . iii . Are receive ≤ 2.5 mg everolimus daily . d. Patients know HIV infection exclude . e. Patients Hepatitis B eligible provide active viral replication . Patients Hepatitis C interferon eligible . 3 . Patients diagnosis hepatocellular carcinoma make radiologic imaging may eligible , provide meet criterion accord American Association Study Liver Disease , AASLD ( Bruix Sherman , 2005 ; Bruix Sherman , 2011 ) 4 . Patients must candidate sorafenib 5 . Must previous systemic anticancer treatment , though previous locoregional therapy allow : . Prior treatment follow allow : transarterial embolization , transarterial chemoembolization , percutaneous ethanol injection , radioembolization , radiofrequency ablation , ablation technique . 6 . Must ChildPugh class A . Patients uncontrolled massive ascites presence hepatic encephalopathy exclude 7 . Must total serum bilirubin ≤ 3 mg/dl 8 . ≥ 18 year age 9 . Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 10 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 11 . Male female patient childproducing potential must agree use contraception avoidance pregnancy measure study 30 day last BBI608 BBI503 dose 12 . Females childbearing potential must negative serum pregnancy test 13 . Aspartate Aminotransferase ( AST ) Alanine transaminase ( ALT ) &lt; 5.0x upper limit normal ( ULN ) 14 . Glomerular filtration rate ( GFR ) &gt; 45 mL/min/1.73m^2 accord CockcroftGault estimation . 13 . Hemoglobin ≥ 8.5 mg/dl 14 . Absolute neutrophil count ≥ 1.5 x 10^9/L 15 . Platelets ≥ 75 x 10^9/L 16 . Life expectancy ≥ 3 month Exclusion Criteria 1 . Previous treatment sorafenib 2 . Patients know hypersensitivity sorafenib component sorafenib . 3 . Previous systemic antivascular endothelial growth factor ( VEGF ) prior systemic anticancer therapy , include prior treatment systemic agent regorafenib , ramucirumab , pazopanib , experimental agent brivanib . 4 . Have surgical procedure require general anesthesia inpatient hospitalization recovery le 4 week prior begin protocol therapy . 5 . Have locoregional procedure treatment hepatocellular carcinoma ( percutaneous , transarterial , radioablative procedure ) less 4 week prior begin protocol therapy . Protocol therapy may begin minimum 4 week procedure provide follow criterion meet : 1 . There progression disease document RECIST 1.1 2 . All adverse event procedure resolve deem irreversible patient meet inclusion criterion . 6 . Any known symptomatic untreated brain metastasis require increase steroid dose within 2 week prior start study . Patients treat brain metastasis must stable 4 week completion treatment . Patients must clinical symptom brain metastasis must either steroids stable dose steroid least 2 week prior protocol enrollment . Patients know leptomeningeal metastasis exclude , even treat . 7 . Pregnant breastfeed 8 . Significant gastrointestinal disorder ( ) , ( e.g. , Crohn 's disease , ulcerative colitis , extensive gastric small intestine resection ) , opinion treat investigator , absorption oral medication may impair . 9 . Unable unwilling swallow BBI608 , BBI503 , sorafenib capsule tablets 10 . Uncontrolled intercurrent illness include , limited : ongoing active infection , clinically significant nonhealing heal wound , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , significant pulmonary disease ( shortness breath rest mild exertion ) , uncontrolled infection psychiatric illness/social situation would limit compliance study requirement ( e.g . reliable transportation ) . 11 . Subjects history another primary cancer , exception : ) curatively resect nonmelanoma skin cancer ; b ) curatively treated cervical carcinoma situ ; c ) primary solid tumor know active disease present , opinion investigator , affect patient outcome set current hepatocellular carcinoma diagnosis . 12 . Abnormal ECGs clinically significant QT prolongation ( QTc &gt; 480 msec ) , clinically significant cardiac enlargement hypertrophy , new bundle branch block , sign active ischemia . Patients evidence prior infarction New York Heart Association ( NYHA ) functional class II , III , IV exclude , patient mark arrhythmias Wolff Parkinson White pattern complete atrioventricular ( AV ) dissociation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>